A phase I study of XL228, a multitargeted protein kinase inhibitor, in patients (pts) with solid tumors or multiple myeloma. Background: BMS-754807 is a potent reversible inhibitor of IGF-1R and IR ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results